| AASLD

Nuclear Sensor Interferon‐Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression

Read more about Nuclear Sensor Interferon‐Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression

Yuanyuan Yang, Xinzhuan Zhao, Ziyu Wang, Wangqin Shu, Lijie Li, Yuqi Li, Zhiwei Guo, Bo Gao, Sidong Xiong – 12 August 2019

Hepatitis C Virus Mediated Inhibition of miR‐181c Activates ATM Signaling and Promotes Hepatocyte Growth

Read more about Hepatitis C Virus Mediated Inhibition of miR‐181c Activates ATM Signaling and Promotes Hepatocyte Growth

Tapas Patra, Keith Meyer, Ratna B. Ray, Ranjit Ray – 10 August 2019

Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus

Read more about Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus

Erwan Atcheson, Wenqin Li, Carly M. Bliss, Senthil Chinnakannan, Kathrin Heim, Hannah Sharpe, Claire Hutchings, Isabelle Dietrich, Dung Nguyen, Amit Kapoor, Michael A. Jarvis, Paul Klenerman, Eleanor Barnes, Peter Simmonds – 10 August 2019

Tumor‐Selective Altered Glycosylation and Functional Attenuation of CD73 in Human Hepatocellular Carcinoma

Read more about Tumor‐Selective Altered Glycosylation and Functional Attenuation of CD73 in Human Hepatocellular Carcinoma

Karel P. Alcedo, Andres Guerrero, Venkatesha Basrur, Dong Fu, Monea L. Richardson, Joshua S. McLane, Chih‐Chiang Tsou, Alexey I. Nesvizhskii, Theodore H. Welling, Carlito B. Lebrilla, Carol A. Otey, Hong Jin Kim, M. Bishr Omary, Natasha T. Snider – 9 August 2019 – CD73, a cell‐surface N‐linked glycoprotein that produces extracellular adenosine, is a novel target for cancer immunotherapy. Although anti‐CD73 antibodies have entered clinical development, CD73 has both protumor and antitumor functions, depending on the target cell and tumor type.

LiverLearning®: 2019 Webinar: HBV Reactivation: How to Approach the Immunosuppressed Patient

Read more about LiverLearning®: 2019 Webinar: HBV Reactivation: How to Approach the Immunosuppressed Patient

This webinar will review the latest approaches in the management of the immunosuppressed patient in the context of HBV reactivation, including screening, risk stratification and indication for antiviral treatment. The focus of management will be on both the oncologic and non-oncologic patient.

Letter to the Editor: Re: Noninvasive Tests in Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Critical Insights from STELLAR Trials

Read more about Letter to the Editor: Re: Noninvasive Tests in Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Critical Insights from STELLAR Trials

Saumya Pandey – 8 August 2019

Six‐Transmembrane Epithelial Antigen of the Prostate 3 Deficiency in Hepatocytes Protects the Liver Against Ischemia‐Reperfusion Injury by Suppressing Transforming Growth Factor‐β‐Activated Kinase 1

Read more about Six‐Transmembrane Epithelial Antigen of the Prostate 3 Deficiency in Hepatocytes Protects the Liver Against Ischemia‐Reperfusion Injury by Suppressing Transforming Growth Factor‐β‐Activated Kinase 1

Wen‐Zhi Guo, Hong‐Bo Fang, Sheng‐Li Cao, San‐Yang Chen, Jie Li, Ji‐Hua Shi, Hong‐Wei Tang, Yi Zhang, Pei‐Hao Wen, Jia‐Kai Zhang, Zhi‐Hui Wang, Xiao‐Yi Shi, Chun Pang, Han Yang, Bo‐Wen Hu, Shui‐Jun Zhang – 8 August 2019

Reply:

Read more about Reply:

Feng Zhou, Jianghua Zhou, Wenxin Wang, Xiao‐Jing Zhang, Yan‐Xiao Ji, Peng Zhang, Zhi‐Gang She, Lihua Zhu, Jingjing Cai, Hongliang Li – 7 August 2019

Letter to the Editor: Prevalence of NAFLD in China: What Did We Learn From the Recent Meta‐Analysis?

Read more about Letter to the Editor: Prevalence of NAFLD in China: What Did We Learn From the Recent Meta‐Analysis?

Yuankai Wu, Yee Hui Yeo, Mindie H. Nguyen, Ramsey C. Cheung – 7 August 2019

Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis

Read more about Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis

Kavita Radhakrishnan, Adrian M. Di Bisceglie, K. Rajender Reddy, Joseph K. Lim, Josh Levitsky, Mohamed A. Hassan, Jama M. Darling, Jordan J. Feld, Lucy Akushevich, Monika Vainorius, David R. Nelson, Michael W. Fried, Robert S. Brown, Norah A. Terrault – 7 August 2019 – Recent studies have suggested a negative impact of hepatocellular carcinoma (HCC) on sustained virologic response (SVR) to hepatitis C virus (HCV) direct acting antivirals (DAAs).

Subscribe to